Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19

Berlin, Germany, June 24 (Korea Bizwire) – Berlin Cures Holding AG, a biotech company developing aptamers for autoimmune diseases, today announces that it is evaluating BC 007, a β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product, for the treatment of COVID-19. A Phase II/III clinical trial is scheduled to start in the second half of 2020. Results from [...]